Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors

Summary

Amberstone Biosciences and Shanghai Henlius Biotech entered into a collaboration and license agreement for conditionally activated T-cell engagers targeting solid tumors. The partnership combines Amberstone's pH-gated oncology technology with Henlius's commercial capabilities.